Literature DB >> 58871

The immunopathology of herpes gestationis. Immunofluorescence studies and characterization of "HG factor".

R E Jordon, K G Heine, G Tappeiner, L L Bushkell, T T Provost.   

Abstract

Nine skin biopsies from seven herpes gestationis patients were studied by immunofluorescence (IF) techniques. Basement membrane zone (BMZ) deposition of C3 and properdin was present in all nine skin specimens, while IgG deposition was apparent in only one. With in vitro C3 IF staining, positive BMZ staining (HG factor activity) was noted with all seven of our patients' serum samples tested. By standard indirect IF staining, however, only one of these serum samples contained BMZ antibodies of the IgG type. Two cord serum samples, tested by these same methods, yielded positive in vitro C3 staining (HG factor activity) but negative indirect IF staining (IgG). HG factor activity was found to be stable at 56 degrees C for 30 min and in two of three specimens at 56 degrees C for 1 h. Treatment of the complement source (normal human serum) used in the in vitro C3 staining assay with Mg2-EGTA or use of C2-deficient serum as the complement source inhibited HG factor activity. HG factor blocked the specific staining of the BMZ of normal human skin by labeled bullous pemphigoid antibodies. By sucrose density gradient ultracentrifugation and gel chromatography (Sephadex G-200), HG factor activity eluted with IgG-containing fractions. The highly purified IgG fraction of two herpes gestationis sera was also positive for HG factor activity. Our studies suggest that HG factor is an IgG antibody that may not be demonstrable by conventional IF methods, but which activates the classical complement pathway.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 58871      PMCID: PMC436801          DOI: 10.1172/JCI108412

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  The complement system in bullous pemphigoid. III. Fixation of C1q and C4 by pemphigoid antibody.

Authors:  R E Jordon; J M Nordby; H Milstein
Journal:  J Lab Clin Med       Date:  1975-11

2.  Immunologic phenomena in herpes gestationis.

Authors:  S Jablonska; T P Chorzelski; E H Beutner; E Maciejowska; G Rzesa
Journal:  Arch Dermatol Forsch       Date:  1975-07-18

3.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

4.  DISC ELECTROPHORESIS. I. BACKGROUND AND THEORY.

Authors:  L ORNSTEIN
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

5.  [A micro-method of immuno-electrophoresis].

Authors:  J J SCHEIDEGGER
Journal:  Int Arch Allergy Appl Immunol       Date:  1955

6.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

7.  Determination of protein: a modification of the Lowry method that gives a linear photometric response.

Authors:  E F Hartree
Journal:  Anal Biochem       Date:  1972-08       Impact factor: 3.365

8.  The C3-activator system: an alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

9.  Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.

Authors:  R D Schreiber; R G Medicus; O Gïtze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

10.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases.

Authors:  J R Stanley
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

2.  Complement fixation by Brazilian Pemphigus foliaceus autoantibodies.

Authors:  S Kawana; L A Diaz; E A Rivitti; W D Geoghegan; R E Jordon
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

3.  High frequency of histocompatibility antigens HLA-DR3 and DR4 in herpes gestations.

Authors:  J K Shornick; P Stastny; J N Gilliam
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

4.  Pemphigoid gestationis.

Authors:  Céline M J G Lardenoije; Marije van de Water; Helena J M M Mertens; Ed T C M Gondrie
Journal:  BMJ Case Rep       Date:  2011-02-08

5.  The role of complement in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; S J Swartz; J A Fairley; G O Till; J L Troy; L A Diaz
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.

Authors:  Z Liu; L A Diaz; J L Troy; A F Taylor; D J Emery; J A Fairley; G J Giudice
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

7.  Herpes gestationis: studies on the binding characteristics, activity and pathogenetic significance of the complement-fixing factor.

Authors:  J A Carruthers; A R Ewins
Journal:  Clin Exp Immunol       Date:  1978-01       Impact factor: 4.330

8.  Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice.

Authors:  Z Lazarova; C Yee; T Darling; R A Briggaman; K B Yancey
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

Review 9.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

10.  Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen.

Authors:  L H Morrison; R S Labib; J J Zone; L A Diaz; G J Anhalt
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.